Moderna Shares Slide Sharply After FDA Refuses to Review Flu Vaccine Application
Moderna, Inc. (NASDAQ: MRNA) tumbled sharply this week after the U.S. Food and Drug Administration (FDA) announced it would not review the company’s application for its experimental mRNA-based influenza vaccine, mRNA-1010, underscoring a significant regulatory setback for the biotech giant. (turn0search6; turn0search26)
? Why the FDA Refused to Review the Application
The FDA’s “refuse‐to-file” decision was based not on safety or efficacy concerns, but rather on methodological issues with the vaccine’s Phase 3 trial design. Regulators said Moderna’s study compared mRNA-1010 to a standard-dose flu vaccine that did not represent the best available standard of care, particularly for older adults, meaning the study was not “adequate and well-controlled” under the agency’s current review standards. Moderna has publicly pushed back on this interpretation, saying the trial design was previously aligned with FDA guidance.
? Strategic Setback for Vaccine Ambitions
The refusal to review the mRNA-1010 application is a blow to Moderna’s efforts to establish itself in the seasonal influenza vaccine market — a segment seen as a key growth driver as revenue from its COVID-19 vaccines has declined. FDA’s move comes amid evolving regulatory attitudes toward mRNA vaccines and stricter expectations for clinical evidence.
The decision not only affects the potential U.S. launch of mRNA-1010 but also clouds expectations for projected revenue from standalone flu vaccines and potential flu/COVID combination shots — products that had been expected to contribute significantly to Moderna’s longer-term financial targets.
? Global Development Path Still Open
Despite the U.S. setback, Moderna’s mRNA-1010 influenza vaccine is still under review in other major markets, including the European Union, Canada and Australia. The company has indicated it plans to pursue reviews outside the U.S. and has requested a meeting with FDA officials to clarify the path forward for potential resubmission.
